Trump’s Tariffs Threaten US Drug Affordability The Value of USFDA-Approved Indian Pharma
The recent announcement of 50% tariffs on Indian exports by former President Trump has sent ripples through global trade, sparking intense concern within the pharmaceutical industry. While pharmaceuticals have thus far escaped these punitive measures, there are mounting threats of higher tariffs on imported drugs from India—a move with enormous potential repercussions for both American and Indian consumers.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
